Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1741 to 1755 of 9128 results

  1. Glofitamab for treating relapsed or refractory mantle cell lymphoma

    Awaiting development Reference number: GID-TA12447 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Garetosmab for preventing heterotopic ossification and flare ups associated with fibrodysplasia ossificans progressiva [ID3772]

    Awaiting development Reference number: GID-TA12522 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Secukinumab for treating relapsed polymyalgia rheumatica ID6599

    In development Reference number: GID-TA11806 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Endoscopic submucosal dissection knives for the resection of complex colorectal polyps with suspected submucosal invasion

    In development Reference number: GID-HTG10883 Expected publication date:  11 February 2027

    HealthTech guidance
    In development

  5. Urinary biomarker tests to detect bladder cancer

    Awaiting development Reference number: GID-HTG10903 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  6. Lotilaner for treating moderate to severe demodex blepharitis

    Awaiting development Reference number: GID-TA12520 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Headaches (update): Prophylactic treatment of migraine - Candesartan

    In development Reference number: GID-NG10472 Expected publication date:  17 February 2027

    NICE guideline
    In development

  8. Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]

    Awaiting development Reference number: GID-TA10823 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765]

    Awaiting development Reference number: GID-TA11050 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development Reference number: GID-TA11087 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]

    Awaiting development Reference number: GID-TA11162 Expected publication date:  28 July 2027

    Technology appraisal guidance
    Awaiting development

  12. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477]

    Awaiting development Reference number: GID-TA11271 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467]

    Awaiting development Reference number: GID-TA11305 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]

    Awaiting development Reference number: GID-TA11383 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747]

    Awaiting development Reference number: GID-TA11404 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development